Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.66 |
| ▸ | HTT | P42858 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | CASP3 | P42574 | 1/20 | 0.64 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.64 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | IDH1 | O75874 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3202901 | 0.94 | HTT (0.62) | MEN1KMT2AHTTLMNANPC1 | |
| SCHEMBL14600412 | 0.94 | HTT (0.60) | MEN1KMT2AHTTLMNANPC1 | |
| SCHEMBL5027770 | 0.87 | HTT (0.54) | MEN1KMT2AHTTLMNANPC1 | |
| SCHEMBL20815511 | 0.84 | ALDH1A1 (0.56) | MEN1KMT2AHTTLMNANPC1 | |
| SCHEMBL12228592 | 0.83 | AR (0.49) | HTTMAPTSLC2A1TSHR | |
| SCHEMBL29666354 | 0.83 | AR (0.49) | HTTMAPTSLC2A1TSHR | |
| SCHEMBL16303890 | 0.81 | EPHX1 (0.58) | MEN1KMT2AHTTLMNANPC1 | |
| SCHEMBL30681937 | 0.81 | HPGD (0.51) | MEN1KMT2AHTTNPC1RAB9A | |
| SCHEMBL941486 | 0.81 | HPGD (0.51) | MEN1KMT2AHTTNPC1RAB9A | |
| SCHEMBL15559868 | 0.81 | HTT (0.52) | MEN1KMT2AHTTLMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004735-A1 | Method for inhibiting the replication of herpes viruses | AICURIS GMBH & CO. KG (DE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004735-A1 | Method for inhibiting the replication of herpes viruses | AICURIS GMBH & CO. KG (DE) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004735-A1 | Method for inhibiting the replication of herpes viruses | RPL35, PCNA, MCM5 | MEN1 2473/4885KMT2A 831/4885HTT 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.